论文部分内容阅读
目的回顾性分析他汀类与心血管药物配伍的安全性。方法共收集120名合并高血脂的患者随机平均分为4组,根据配伍的药物分为抗心力衰竭药物组、钙通道阻滞药物组,抗高血压药物组和抗心律失常药物组,每组均与他汀类药物配伍,进行不同代表药物试验,观察、记录各组的药物代谢数据。结果他汀类药物与抗心衰药物、钙通道阻滞药物、血管紧张素转换酶抑制剂可联合应用,相对较安全。与抗心律失常药物配伍使用易出现不良反应,应当避免。结论他汀类药物与心血管药物配伍使用时多为协同作用,可增加药效,但少数药物会出现药物动力学的相互影响,应适当减少药量并考虑对药效的影响。
Objective To retrospectively analyze the safety of compatibility of statins and cardiovascular drugs. Methods A total of 120 patients with hyperlipidemia were randomly divided into four groups randomly divided into four groups: anti-heart failure drug group, calcium channel block drug group, antihypertensive drug group and antiarrhythmic drug group, and each group All with statins compatibility, different representatives of drug testing, observation, record of each group of drug metabolism data. Results Statins and anti-heart failure drugs, calcium channel blockers, angiotensin-converting enzyme inhibitors can be combined, relatively safe. Compatibility with anti-arrhythmic drugs prone to adverse reactions, should be avoided. Conclusions When statins and cardiovascular drugs are used in combination, synergism may increase synergistic effect. However, the interaction of pharmacokinetics of a few drugs may appear. Therefore, the dosage should be appropriately reduced and the effect on pharmacodynamics should be considered.